Session Details
[F2]Flash Talk (Even no.)
Tue. Mar 3, 2026 5:40 PM - 6:14 PM JST
Tue. Mar 3, 2026 8:40 AM - 9:14 AM UTC
Tue. Mar 3, 2026 8:40 AM - 9:14 AM UTC
Kobe Portopia Hotel(South Wing 1F Ohwada)
[F2-82]Computationally guided T-cell vaccine design for protection against invasive non-typhoidal Salmonella (iNTS)
Sebastian Kapell1,4, *Eugen Bauer1, Sarunporn Tandhavanant5, Agnieszka Gromadka1, Anja Moesch2,4, Daiki Mori3, Kazuhide Onoguchi3, Kaïdre Bendjama1,4, Toshio Kodama5 (1. NEC Oncoimmunity AS (Norway), 2. NEC Laboratories Europe (Germany), 3. NEC Corporation (Japan), 4. Department of Vaccine Informatics, Institute of Tropical Medicine, Nagasaki University (Japan), 5. Department of Bacteriology, Institute of Tropical Medicine, Nagasaki University (Japan))
[F2-84]Enhanced Immune Activation by DEVOTE-HFQ: Dendritic Cell-Derived Extracellular Vesicles Optimized via Tailored Engineering Using HFQ Lipid
*Makoto Matsumoto1, Yoshimasa Tanaka1, Masayuki Kaneko1, Koji Matsuhisa1, Shigeru Kawakami1 (1. Nagasaki University Graduate School of Biomedical Sciences (Japan))
[F2-86]mRNA-LNP Technology Enabling Optimized Local Expression and Reduced Inflammation Induction after Intramuscular Injection
*Yusuke Ushiroda2, Makoto Matsumoto1, Kazuya Okami1, Shintaro Fumoto1,2, Riku Takayama2, Akari Kiguchi2, Hidefumi Mukai1,2, Shigeru Kawakami1,2 (1. Nagasaki University Graduate School of Biomedical Sciences (Japan), 2. Nagasaki University Pharmaceutical sciences (Japan))
[F2-88]T-Cell Immunogenicity of AI-Predicted Malaria Vaccine Elements Assessed by IFN-γ Enzyme-Linked Immunospot Assay
*Shara Bakytbek1,2,3, Agnieszka Gromadka4, Wataru Kagaya3,5, Huai Chuang3,6, Yarob Ibraheem1,2,3, Farzaneh Valanezhad1,2,3, Ayako Hyuga1,2,3, Marius Gheorghe4, Daiki Miura7, Alexandru Odainic4, Shin-Ichi Inoue2,8, Shusaku Mizukami3,9, Satoshi Kaneko3,5, Kazuhide Onoguchi7, Sebastian Kapell4,10, Kaidre Bendjama4, Osamu Kaneko3,6, Shinjiro Hamano1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. NEC Oncoimmunity AS, Oslo (Norway), 5. Department of Eco-epidemiology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 6. Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 7. AI Drug Development Division, NEC Corporation, Tokyo (Japan), 8. Department of Molecular Microbiology and Immunology, Division of Immunology, Nagasaki University, Nagasaki (Japan), 9. Department of Immune Regulations, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan), 10. Department of Vaccine Informatics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki (Japan))
[F2-90]Construction and evaluation of novel AAV vector vaccines aimed at effective immune induction
*Ken Sugo1, Hiroshi Ueki2,3,4, Yuji Tsunekawa1, Emiko Urano5, Yukage Kobari1, Yasunari Matsuzaka1, Koji Kobiyama6, Guillermo Posadas-Herrera1, Hiromi Hayashita-Kinoh1, Mikako Wada1, Yukihiko Hirai1, Yasushi Soda1, Yasuhiro Yasutomi5, Ken J. Ishii6,7,8,9,10, Seiya Yamayoshi2,3,4, Yoshihiro Kawaoka2,3,4, Takashi Okada1 (1. Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo (Japan), 2. Division of Virology, The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Global Viral Diseases, National Institute of Global Health and Medicine (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA) (Japan), 5. Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) (Japan), 6. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (Japan), 7. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo (Japan), 8. Graduate School of Medicine and Faculty of Medicine, The University of Tokyo (Japan), 9. International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 10. Laboratory of Vaccine Science, Immunology Frontier Research Center, The University of Osaka (Japan))
[F2-92]Development of a next-generation mock-up vaccine using an intraepidermal needle-free vaccination device
*Keiichi Motoyama1,2, Masahiro Ogura2, Riru Onigahara2, Shunsuke Sasaki3, Naoki Kishimoto1,3, Shogo Msisumi1,3, Toru Taharabaru1,2, Taishi Higashi1,2, Hirotoshi Adachi4, Masahiko Kikuchi1,5 (1. Vaccine Development Research Center, Kumamoto University (Japan), 2. Graduate School of Pharmaceutical Sciences, Kumamoto University (Japan), 3. Department of Environmental and Molecular Health Sciences, Kumamoto University (Japan), 4. PassPort Technologies, Inc (USA), 5. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (Japan))
[F2-94]Expression and chromatin accessibility quantitative trait loci uncover genetic regulation and immune mechanisms in finely sorted 29 immune cell types
*Hiroki Kitaoka1,2, Rintaro Fujimoto1,2,3, Saya Hisano1,3, Akiko Oguchi1,4, Raku Son1,4, Ryuya Edahiro1,3, Go Sato1,3, Yoshihiko Tomofuji1,2, Matteo Maurizio Guerrini1, Yasuhiro Murakawa1,4, Akari Suzuki1, Yukinori Okada1,2,3, Kazuhiko Yamamoto1 (1. RIKEN Integrative Medical Sciences (Japan), 2. The University of Tokyo (Japan), 3. The University of Osaka (Japan), 4. Kyoto University (Japan))
[F2-96]Multi-layered single-cell genomics deconvolutes biological mechanisms underlying clonal hematopoiesis and mitochondrial heteroplasmyin infectious & autoimmune diseases
*Go Sato1,2,3, Ryuya Edahiro2,3, Tomohiro Yata2, Kotaro Ogawa2, Tatsuhiko Naito1,2, Kyuto Sonehara1,2,3, Ryunosuke Saiki4, Shinichi Namba1,2,3, Yuya Shirai2,3, Kenichi Yamamoto2, Seishi Ogawa4, Hideki Mochizuki2, Noriko Isobe5, Tatsusada Okuno2, Atsushi Kumanogoh2, Yukinori Okada1,2,3 (1. Graduate School of Medicine, the University of Tokyo (Japan), 2. Graduate School of Medicine, the University of Osaka (Japan), 3. RIKEN Center for Integrative Medical Sciences (Japan), 4. Graduate School of Medicine, Kyoto University (Japan), 5. Graduate School of Medical Sciences, Kyusyu University (Japan))
[F2-98]Confidential
*Rintaro Fujimoto1,2,3, Kotaro Ogawa1, Shinichi Namba1,2,3, Yosuke Ogawa2, Ryuya Edahiro1,3, Kyuto Sonehara1,2, Shiori Tagawa2, Tomohiro Yata1, Yuya Shirai1, Yuji Yamamoto1, Go Sato1,2,3, Chifune Kai1, Tatsuhiko Naito1,2,3, Tatsusada Okuno1, Noriko Isobe4, Yukinori Okada1,2,3 (1. Department of Statistical Genetics, Osaka University Graduate School of Medicine (Japan), 2. The University of Tokyo (Japan), 3. Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences (Japan), 4. Kyushu University (Japan))
[F2-100]5′ single-cell mapping of transcribed enhancers reveals cell-type–specific regulatory changes in aging human skin
*Akiyoshi Senda1,2,3, Akiko Oguchi1,4,5, Raku Son1,4,5, Daisuke Akiyama1,2,6, Yasuhiro Murakawa1,2,4,7 (1. Institute for the Advanced Study of Human Biology, Kyoto University (Japan), 2. Department of Pathology and Biology of Diseases, Graduate School of Medicine, Kyoto University (Japan), 3. Department of Dermatology, Graduate School of Medicine, Kyoto University (Japan), 4. Laboratory for Gene Structure and Regulation, RIKEN Center for Integrative Medical Sciences (Japan), 5. Department of Nephrology, Graduate School of Medicine, Kyoto University (Japan), 6. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University (Japan), 7. IFOM ETS - the AIRC Institute of Molecular Oncology (Italy))
[F2-102]A multi-scale map of protein assemblies in the DNA damage response
*Anton Kratz1 (1. DEJIMA Infectious Disease Research Alliance and The Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan))
[F2-104]Genetics of immune response in monocytes from Japanese healthy donors
*Matteo Guerrini1 (1. RIKEN IMS (Japan))
[F2-106]Sperm and offspring production in a nonobstructive azoospermia mouse model via testicular mRNA delivery using lipid nanoparticles
*Daisuke Mashiko1, Chihiro Emori1, Yuki Hatanaka1, Daisuke Motooka1, Chen Pan1, Yuki Kaneda1, Martin M Matzuk2, Masahito Ikawa1 (1. RIMD, The University of Osaka (Japan), 2. Center for Drug Discovery, Department of Pathology & Immunology, Baylor College of Medicine (USA))
[F2-108]Establishment of recombinant cynomolgus chorionic gonadotropin
*Toshifumi Morimura1, Nao Maeda1, Yuko Abiko1, Azusa Nakayama1, Masatsugu Ema1 (1. Research Center for Animal Life Science, Shiga University of Medical Science (Japan))
[F2-110]Generation and application of humanized mice with human pulmonary alveolar tissues using human induced pleuripotent stem cells in vivo.
*Takeshi Takahashi1, Akira Yamagata2,3, Satoshi Konishi2, Satoshi Ikeo3, Hiroshi Moriyama4, Senye Takahashi2, Naoyuki Sone2, Satoshi Hamada3,5, Atsushi Saito6, Takashi Kawaguchi7, Shu Hisata8, Akira Niwa2, Toshiaki Kikuchi9, Hirofumi Chiba6, Megumu K Saito2, Koichi Hagiwara8, Toyohiro Hirai3, Mio Iwasaki10, Takuya Yamamoto10,11,12, Shimpei Gotoh2 (1. Division of Multiverse Medical Sciences, CIEM (Japan), 2. Center for iPS Cell Research and Application (CiRA), Kyoto University (Japan), 3. Departmentn of Respiratory Medicine, Graduate School of Medicine, Kyoto University (Japan), 4. Respiratory Center, National Hospital Organization Nishiniigata Chuo Hospital (Japan), 5. Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University (Japan), 6. Department of Respiratory Medicine and Allergoloty, Sapporo Medical University School of Medicine (Japan), 7. Kawaguchi Respiratory Clinic (Japan), 8. Division of Pulmonary Medicine, Department of Medicine, Jichi medical University (Japan), 9. Department of Respiratory Medicine and Infectious Diseases, Niigata Univerisity Graduate School of Medical and Dental Sciences (Japan), 10. Department of Life Science Frontiers, CiRA, Kyoto University (Japan), 11. Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University (Japan), 12. Medical-risk Avoidance Based on iPS cells team, RIKEN Center for Adcanced Intelligence Project (AIP) (Japan))
[F2-112]A Novel Immunodeficient Hyperglycemic Mouse Carrying the Ins1 Akita Mutation
Kenta Nakano1, Motohito Goto2, Riichi Takahashi2, *TADASHI OKAMURA1 (1. Japan Institute for Health Security (JIHS) (Japan), 2. Central Institute for Experimental Medicine and Life Science (CIEM) (Japan))
[F2-114]Development of mRNA–LNP Formulations with Reduced Inflammatory Properties
*Yusuke Sato1, Rikuto Taneda1, Mai Yakuwa1, Mina Sato1, Hideyoshi Harashima1 (1. Graduate School of Pharmaceutical Sciences, Hokkaido University (Japan))
[F2-116]URA as a Co-Creator: Supporting Research through Case Studies and Future Perspectives
*Yuko Yamamoto1 (1. Chiba University, Synergy Institute for Futuristic Mucosal Vaccine Research and Development (Japan))
[F2-118]Structural biology approach to fight
infectious diseases
*Yoshiaki Kise1, Kanata Matsumoto1, Kazuhiro Sawada1, Hana Matsushita1, Shin Mukai1, Osamu Nureki1 (1. Department of Biological Sciences, The University of Tokyo (Japan))
[F2-120]Structural and synthetic biology approaches to combat viral pandemic
*Osamu Nureki1 (1. Graduate School of Science, The University of Tokyo (Japan))
[F2-122]Global Climate-Driven Malaria and Dengue Risk Mapping Using Deep Learning Transformers Under Present and Future Warming Scenarios
*Micheal Teron Pillay1, Mai Le Thi Quynh 2, Yuki Takamatsu1, Tran Vu Phong2, Ratnam Jayanthi3, Kyoko Futami1, Satoshi Kaneko1, Noboru Minakawa1 (1. Institute of Tropical Medicine, Nagasaki University (Japan), 2. National Institute of Hygiene and Epidemiology (Viet Nam), 3. Japan Agency for Marine-Earth Science and Technology (Japan))
[F2-124]Developing a machine learning model to find consistent patterns in unsupervised multimodal omics data
*Dorothy DeMore Ellis1, Jun Seita1 (1. RIKEN IMS (Japan))
[F2-126]Impact of Vaccine Strains on the Persistence of Measles and Rubella Antibodies in a Pediatric Population Using Residual Clinical Samples and Maternal and Child Health Handbook
*Munehiro Furuichi1,2, Yoshifumi Uwamino1,3,4, Kazuma Yagi1,3,4, Masayoshi Shinjoh1,2, Ho Namkoong1,3,4 (1. Division of Infectious Diseases and Infection Control, Keio University Hospital (Japan), 2. Department of Pediatrics, Keio University School of Medicine (Japan), 3. Department of Infectious Diseases, Keio University School of Medicine (Japan), 4. Clinical Infectious Diseases Center, Keio University Hospital (Japan))
[F2-128]Long-term Natural Waning of Humoral Immunity After COVID-19 mRNA Vaccine Booster Doses
*Yoshifumi Uwamino1, Kengo Nagashima2, Ho Namkoong1 (1. Keio University School of Medicine (Japan), 2. Keio University Hospital (Japan))
[F2-130]Building an EDC System as a Comprehensive Research Infrastructure for Respiratory Infectious Diseases in Preparation for the Next Pandemic
*Kazuma Yagi1, Takeshi Arashiro1, Takanori Asakura1, Munehiro Furuichi1, Yoshifumi Uwamino1, Ho Namkoong1 (1. Keio University School of Medicine (Japan))
[F2-132]Identification of Glycoprotein 2 as an Intestinal Defense Factor in Neonates
*NAREN TONGLEGA1,2, Zhongwei Zhang1,2, Sayuri Murasaki1,2, Fujimi Arai1,2,3, Tamami Matsushita1,2, Yosuke Kurashima1,2,3,4,5 (1. Department of Innovative Medicine, Graduate School of Medicine, Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba (Japan), 2. Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba, (Japan), 3. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Department of Human Mucosal Vaccinology, Chiba University Hospital, (Japan), 4. Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine, San Diego, CA, USA. (USA), 5. Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, (Japan))
[F2-134]High-throughput rate-of-kill assay, an innovative approach for prioritization of trypanocidal compounds against Trypanosoma cruzi amastigote stage
Mizuki Hayashishita1,2,3, Michele Lika Furuya1,2, Japheth Kibet Ng’etich4,5,6, Jean-Robert Ioset7, Takeshi Nara8, Takaya Sakura1,2,9, *Daniel Ken Inaoka1,2,9,10 (1. School of Tropical Medicine and Global Health, Nagasaki University (Japan), 2. Department of Infection Biochemistry, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 3. Brazil Research Station, National Research Center for the Control and Prevention of Infectious Diseases (CCPID), Nagasaki University (Japan), 4. Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University (Japan), 5. Program for Nurturing Global Leaders in Tropical and Emerging Communicable Diseases, Graduate School of Biomedical Sciences, Nagasaki University (Japan), 6. Center for Traditional Medicine and Drug Research, Kenya Medical Research Institute (Kenya), 7. Drugs for Neglected Diseases Initiative (Switzerland), 8. Laboratory of Molecular Parasitology, Graduate School of Life Science and Technology, Iryo Sosei University (Japan), 9. Department of Molecular Infection Dynamics, Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 10. Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo (Japan))
[F2-136]Literature Review on Challenges in Development and Administration of Vaccines Against Non-HIV Infections that Include HIV-Positive Individuals
*Miku Shimasaki1, Kyoko Mimura2, Chihiro Nishi2, Izen Ri2, Kaori Muto2,3 (1. Graduate School of Frontier Sciences, The University of Tokyo (Japan), 2. The Institute of Medical Science, The University of Tokyo (Japan), 3. Center for Integrative Medical Sciences, RIKEN (Japan))
[F2-138]Building a Regional Primary Human Airway Epithelial Resource for Mucociliary Clearance Assays and Organoid Host-Response Studies
*Takanori Asakura1, Yu Shionoya2,4, Takuya Ozawa1, Shuhei Azekawa1, Rima Kanai1, Tomoya Tamaki1, Makoto Ishii3, Ho Namkoong4, Koichi Fukunaga1 (1. Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan (Japan), 2. Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan. (Japan), 3. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan (Japan), 4. Department of Infectious Disease, Keio University School of Medicine, Japan (Japan))
[F2-140]Michael acceptor-containing programmed synthetic alkaloid covalently binds host POLE3 and inhibits HBV replication
*Misao Himeno1,2, Nobuto Kaneko3, Yuhi Kobayashi3, Ryo Tanifuji3, Hiroki Kubota4, Haruki Mizoguchi5, Makoto Muroi6, Takehiro Suzuki6, Masaya Sugiyama7, Naoshi Dohmae6, Hiroyuki Osada6, Taketomo Kido2, Atsushi Miyajima2, Hiroki Oguri3 (1. Department of Developmental Medical Sciences, The University of Tokyo (Japan), 2. Laboratory of Cell Growth and Differentiation, Institute for Quantitative Biosciences, The University of Tokyo (Japan), 3. Department of Chemistry, Graduate School of Science, The University of Tokyo (Japan), 4. Department of Applied Chemistry, Graduate School of Engineering, Tokyo University of Agriculture and Technology (Japan), 5. Graduate School of Natural Science and Technology, Okayama University (Japan), 6. Centre for Sustainable Resource Science, RIKEN (Japan), 7. Department of Viral Pathogenesis and Control, National Institute of Global Health and Medicine (Japan))
[F2-142]Development of a Next-Generation PBMC Collection System for Efficient Clinical Research
*Hiromitsu Tazawa1, Osamu Kikuchi1,2, Yuki Furuya1, Yuko Matsuura1, Miki Ohkita1, Kazuhiro Nakamura4, Osamu Segawa4, Kazumi Sawakami4, Hideji Tajima4, Manabu Muto1,3 (1. . Clinical Bio-Resource Center, Kyoto University Hospital (Japan), 2. Center for Cancer Immunotherapy and Immunobiology, Kyoto University (Japan), 3. Ckinical Oncology, Kyoto University Hospital (Japan), 4. Precision System Science Inc. & Universal Bio Research Inc. (Japan))
[F2-144]Efficient recombinant protein–secretion platform for developing vaccines and diagnostics against mycobacterial diseases
*Hiroto Takeuchi1,2, Satoru Mizuno2, Kazuhiro Matsuo2 (1. International Institute for Zoonosis Control (Japan), 2. Institute for Vaccine Research and Development (Japan))
[F2-146]Heterogeneity of Genetic Sequence within Quasi-species of Influenza Virus Revealed by Single-Molecule Sequencing
*Kenji Tamao1, Hiroyuki Noji1, Kazuhito V Tabata1 (1. Department of Applied Chemistry, School of Engineering, The University of Tokyo)
[F2-148]Mathematical Study on Error Catastrophe Avoidance in Influenza Virus
*Soma Kosokabe1, Hiroyuki Noji1, Kazuhito V Tabata1(1. Department of Applied Chemistry, School of Engineering, The University of Tokyo)